Details of the Drug

General Information of Drug (ID: DMUL5EW)

Drug Name
Posaconazole
Synonyms
Noxafil; Spriafil; Posaconazole SP; Posaconazole in combination with MGCD290; SCH56592; Sch 56592; X2N; Noxafil (TN); Noxafil, Posaconazole; SCH-56592; Posaconazole (USAN/INN); Posaconazole [USAN:INN:BAN]; 1-((1S,2S)-1-Ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5S,3R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one; 4-(p-(4-(p-(((3R,5R)-5-(2,4-Difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furyl)methoxy)phenyl)-1-piperazinyl)phenyl)-1-((1S,2S)-1-ethyl-2-hydroxypropyl)-delta(sup 2)-1,2,4-triazolin-5-one; 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one; 4-[4-[4-[4-[[(5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
Indication
Disease Entry ICD 11 Status REF
Aspergillosis 1F20 Approved [1], [2], [3]
Therapeutic Class
Antifungal Agents
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 700.8
Topological Polar Surface Area (xlogp) 4.6
Rotatable Bond Count (rotbonds) 12
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 11
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability
96% of drug becomes completely available to its intended biological destination(s) [5]
Clearance
The drug present in the plasma can be removed from the body at the rate of 4.3 mL/min/kg [6]
Elimination
0.1% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 12;) of 35 hours [6]
Metabolism
The drug is metabolized via UDP glucuronidation [7]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 16.308 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.013% [6]
Vd
The volume of distribution (Vd) of drug is 1774 L [9]
Water Solubility
The ability of drug to dissolve in water is measured as 0.00005 mg/mL [4]
Chemical Identifiers
Formula
C37H42F2N8O4
IUPAC Name
4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
Canonical SMILES
CC[C@@H]([C@H](C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5C[C@](OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F
InChI
InChI=1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3/t26-,27+,35-,37-/m0/s1
InChIKey
RAGOYPUPXAKGKH-XAKZXMRKSA-N
Cross-matching ID
PubChem CID
468595
ChEBI ID
CHEBI:64355
CAS Number
171228-49-2
DrugBank ID
DB01263
TTD ID
D07ABV
VARIDT ID
DR00111
INTEDE ID
DR1316
ACDINA ID
D00542

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Candida Cytochrome P450 51 (Candi ERG11) TTTSOUD CP51_CANAL Inhibitor [10]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [12]
UDP-glucuronosyltransferase 1A1 (UGT1A1)
Main DME 		DEYGVN4 UD11_HUMAN Substrate [13]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Posaconazole (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Posaconazole and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [47]
Ivosidenib DM8S6T7 Major Decreased metabolism of Posaconazole caused by Ivosidenib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [48]
Midostaurin DMI6E0R Major Decreased metabolism of Posaconazole caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [49]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Arn-509. Acute myeloid leukaemia [2A60] [50]
Gilteritinib DMWQ4MZ Major Decreased metabolism of Posaconazole caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [51]
Oliceridine DM6MDCF Major Decreased metabolism of Posaconazole caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [52]
Ivabradine DM0L594 Major Decreased metabolism of Posaconazole caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [47]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Posaconazole and Dronedarone. Angina pectoris [BA40] [53]
Bedaquiline DM3906J Major Decreased metabolism of Posaconazole caused by Bedaquiline mediated inhibition of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [54]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Levalbuterol. Asthma [CA23] [55]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Pirbuterol. Asthma [CA23] [56]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Retigabine. Behcet disease [4A62] [53]
Cariprazine DMJYDVK Major Decreased metabolism of Posaconazole caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [57]
Erdafitinib DMI782S Major Decreased metabolism of Posaconazole caused by Erdafitinib mediated inhibition of CYP450 enzyme. Bladder cancer [2C94] [58]
Pexidartinib DMS2J0Z Major Decreased metabolism of Posaconazole caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [59]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Eribulin. Breast cancer [2C60-2C6Y] [53]
Talazoparib DM1KS78 Moderate Decreased clearance of Posaconazole due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [60]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Posaconazole caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [61]
HKI-272 DM6QOVN Major Decreased metabolism of Posaconazole caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [62]
LY2835219 DM93VBZ Major Decreased metabolism of Posaconazole caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [63]
Esterified estrogens DM9KZDO Moderate Decreased metabolism of Posaconazole caused by Esterified estrogens mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [64]
Tucatinib DMBESUA Moderate Decreased clearance of Posaconazole due to the transporter inhibition by Tucatinib. Breast cancer [2C60-2C6Y] [65]
Palbociclib DMD7L94 Major Decreased metabolism of Posaconazole caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [66]
Quinestrol DMJ6H1Z Moderate Decreased metabolism of Posaconazole caused by Quinestrol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [64]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Posaconazole caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [47]
Bosutinib DMTI8YE Major Decreased metabolism of Posaconazole caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [47]
Trastuzumab Emtansine DMU1LXS Moderate Decreased metabolism of Posaconazole caused by Trastuzumab Emtansine mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [47]
Macitentan DMP79A1 Major Decreased metabolism of Posaconazole caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [67]
PF-04449913 DMSB068 Major Decreased metabolism of Posaconazole caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [68]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Posaconazole and Olodaterol. Chronic obstructive pulmonary disease [CA22] [56]
Vilanterol DMF5EK1 Moderate Decreased metabolism of Posaconazole caused by Vilanterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [69]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Posaconazole and Indacaterol. Chronic obstructive pulmonary disease [CA22] [56]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Arformoterol. Chronic obstructive pulmonary disease [CA22] [56]
Levomilnacipran DMV26S8 Major Decreased metabolism of Posaconazole caused by Levomilnacipran mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [70]
Regorafenib DMHSY1I Moderate Decreased metabolism of Posaconazole caused by Regorafenib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [47]
Intedanib DMSTA36 Moderate Decreased metabolism of Posaconazole caused by Intedanib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [71]
Drospirenone DM1A9W3 Major Decreased metabolism of Posaconazole caused by Drospirenone mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [47]
Levonorgestrel DM1DP7T Moderate Decreased metabolism of Posaconazole caused by Levonorgestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [64]
Ulipristal DMBNI20 Minor Decreased metabolism of Posaconazole caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [50]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Probucol. Coronary atherosclerosis [BA80] [53]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Posaconazole and Pasireotide. Cushing syndrome [5A70] [53]
Osilodrostat DMIJC9X Major Decreased metabolism of Posaconazole caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [50]
Ivacaftor DMZC1HS Major Decreased metabolism of Posaconazole caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [47]
Rivaroxaban DMQMBZ1 Major Decreased metabolism of Posaconazole caused by Rivaroxaban mediated inhibition of CYP450 enzyme. Deep vein thrombosis [BD71] [47]
Vilazodone DM4LECQ Major Decreased metabolism of Posaconazole caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [72]
OPC-34712 DMHG57U Major Decreased metabolism of Posaconazole caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [73]
Polatuzumab vedotin DMF6Y0L Major Decreased metabolism of Posaconazole caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [74]
[3H]estrone-3-sulphate DMGPF0N Moderate Decreased metabolism of Posaconazole caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [75]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [53]
Ospemifene DMC4GEI Moderate Decreased metabolism of Posaconazole caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [76]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Posaconazole and Deutetrabenazine. Dystonic disorder [8A02] [77]
Ingrezza DMVPLNC Major Additive CNS depression effects by the combination of Posaconazole and Ingrezza. Dystonic disorder [8A02] [78]
Lacosamide DMVM6QR Moderate Decreased metabolism of Posaconazole caused by Lacosamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [47]
Cannabidiol DM0659E Minor Decreased metabolism of Posaconazole caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [50]
Bay 80-6946 DMLOS5R Major Decreased clearance of Posaconazole due to the transporter inhibition by Bay 80-6946. Follicular lymphoma [2A80] [79]
Tazemetostat DMWP1BH Major Decreased metabolism of Posaconazole caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [80]
Solifenacin DMG592Q Major Decreased metabolism of Posaconazole caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [47]
Mirabegron DMS1GYT Minor Decreased metabolism of Posaconazole caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [81]
Dexlansoprazole DM1DBV5 Moderate Decreased absorption of Posaconazole due to altered gastric pH caused by Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [82]
Ripretinib DM958QB Major Decreased metabolism of Posaconazole caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [47]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Sunitinib. Gastrointestinal stromal tumour [2B5B] [53]
Avapritinib DMK2GZX Major Decreased metabolism of Posaconazole caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [50]
Colchicine DM2POTE Major Decreased metabolism of Posaconazole caused by Colchicine mediated inhibition of CYP450 enzyme. Gout [FA25] [83]
Boceprevir DMBSHMF Moderate Decreased metabolism of Posaconazole caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [84]
ABT-450 DMFW860 Moderate Decreased metabolism of Posaconazole caused by ABT-450 mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [50]
Simeprevir DMLUA9D Major Decreased metabolism of Posaconazole caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [47]
Telaprevir DMMRV29 Moderate Decreased metabolism of Posaconazole caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [84]
Daclatasvir DMSFK9V Major Decreased metabolism of Posaconazole caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [50]
GS-5885 DMSL3DX Moderate Decreased clearance of Posaconazole due to the transporter inhibition by GS-5885. Hepatitis virus infection [1E50-1E51] [85]
Brentuximab vedotin DMWLC57 Moderate Decreased clearance of Posaconazole due to the transporter inhibition by Brentuximab vedotin. Hodgkin lymphoma [2B30] [86]
MK-1439 DM215WE Minor Decreased metabolism of Posaconazole caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [87]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [88]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Posaconazole caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [89]
Dolutegravir DMCZGRE Minor Decreased metabolism of Posaconazole caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [90]
Etravirine DMGV8QU Moderate Decreased metabolism of Posaconazole caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [91]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [53]
Rilpivirine DMJ0QOW Moderate Decreased metabolism of Posaconazole caused by Rilpivirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [92]
Maraviroc DMTL94F Major Decreased metabolism of Posaconazole caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [93]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Posaconazole and Mipomersen. Hyper-lipoproteinaemia [5C80] [94]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Posaconazole and Teriflunomide. Hyper-lipoproteinaemia [5C80] [53]
BMS-201038 DMQTAGO Major Decreased metabolism of Posaconazole caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [47]
Sodium zirconium cyclosilicate DMCSLZ4 Moderate Decreased absorption of Posaconazole due to altered gastric pH caused by Sodium zirconium cyclosilicate. Hyperkalaemia [5C76] [50]
Aliskiren DM1BV7W Moderate Decreased metabolism of Posaconazole caused by Aliskiren mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [53]
Levamlodipine DM92S6N Moderate Decreased metabolism of Posaconazole caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [95]
Tolvaptan DMIWFRL Major Decreased metabolism of Posaconazole caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [47]
TP-434 DM5A31S Minor Decreased metabolism of Posaconazole caused by TP-434 mediated inhibition of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [96]
Berotralstat DMWA2DZ Major Decreased clearance of Posaconazole due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [97]
Suvorexant DM0E6S3 Major Decreased metabolism of Posaconazole caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [47]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Posaconazole caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [98]
ITI-007 DMUQ1DO Major Decreased metabolism of Posaconazole caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [99]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Posaconazole and Polyethylene glycol. Irritable bowel syndrome [DD91] [50]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Posaconazole and Phenolphthalein. Irritable bowel syndrome [DD91] [53]
Eluxadoline DMYZ0P1 Moderate Decreased metabolism of Posaconazole caused by Eluxadoline mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [100]
Naloxegol DML0B41 Major Decreased metabolism of Posaconazole caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [47]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Posaconazole and Crizotinib. Lung cancer [2C25] [101]
Brigatinib DM7W94S Major Decreased metabolism of Posaconazole caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [102]
Ceritinib DMB920Z Major Decreased metabolism of Posaconazole caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [47]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Posaconazole caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [103]
PF-06463922 DMKM7EW Major Decreased metabolism of Posaconazole caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [104]
Osimertinib DMRJLAT Major Decreased metabolism of Posaconazole caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [105]
Pralsetinib DMWU0I2 Major Decreased metabolism of Posaconazole caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [106]
Capmatinib DMYCXKL Major Decreased metabolism of Posaconazole caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [107]
Selpercatinib DMZR15V Major Decreased metabolism of Posaconazole caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [50]
Artemether DM48QOT Major Decreased metabolism of Posaconazole caused by Artemether mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [47]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Posaconazole and Hydroxychloroquine. Malaria [1F40-1F45] [108]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [50]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Posaconazole and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [109]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Posaconazole and Idelalisib. Mature B-cell leukaemia [2A82] [110]
GDC-0199 DMH0QKA Major Decreased metabolism of Posaconazole caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [111]
IPI-145 DMWA24P Major Decreased metabolism of Posaconazole caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [112]
Acalabrutinib DM7GCVW Major Decreased metabolism of Posaconazole caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [113]
Ibrutinib DMHZCPO Major Decreased metabolism of Posaconazole caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [47]
Ponatinib DMYGJQO Major Decreased metabolism of Posaconazole caused by Ponatinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [47]
Arry-162 DM1P6FR Moderate Decreased clearance of Posaconazole due to the transporter inhibition by Arry-162. Melanoma [2C30] [47]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Posaconazole and Vemurafenib. Melanoma [2C30] [53]
Selumetinib DMC7W6R Major Decreased metabolism of Posaconazole caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [114]
LGX818 DMNQXV8 Major Decreased metabolism of Posaconazole caused by LGX818 mediated inhibition of CYP450 enzyme. Melanoma [2C30] [115]
Dabrafenib DMX6OE3 Moderate Decreased metabolism of Posaconazole caused by Dabrafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [47]
Ubrogepant DM749I3 Major Decreased metabolism of Posaconazole caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [116]
Rimegepant DMHOAUG Moderate Decreased metabolism of Posaconazole caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [117]
Lasmiditan DMXLVDT Moderate Decreased clearance of Posaconazole due to the transporter inhibition by Lasmiditan. Migraine [8A80] [118]
Flibanserin DM70DTN Major Decreased metabolism of Posaconazole caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [119]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Posaconazole and Siponimod. Multiple sclerosis [8A40] [47]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Posaconazole and Fingolimod. Multiple sclerosis [8A40] [53]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Posaconazole and Ozanimod. Multiple sclerosis [8A40] [120]
Deflazacort DMV0RNS Major Decreased metabolism of Posaconazole caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [50]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Romidepsin. Mycosis fungoides [2B01] [53]
Fedratinib DM4ZBK6 Major Decreased metabolism of Posaconazole caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [50]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Posaconazole and Nilotinib. Myeloproliferative neoplasm [2A20] [53]
Ruxolitinib DM7Q98D Major Decreased metabolism of Posaconazole caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [121]
Vorapaxar DMA16BR Major Decreased metabolism of Posaconazole caused by Vorapaxar mediated inhibition of CYP450 enzyme. Myocardial infarction [BA41-BA43] [47]
Rolapitant DM8XP26 Moderate Decreased clearance of Posaconazole due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [122]
E-2007 DMJDYNQ Minor Decreased metabolism of Posaconazole caused by E-2007 mediated inhibition of CYP450 enzyme. Neuropathy [8C0Z] [50]
Entrectinib DMMPTLH Major Decreased metabolism of Posaconazole caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [47]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Lofexidine. Opioid use disorder [6C43] [53]
S-297995 DM26IH8 Moderate Decreased metabolism of Posaconazole caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [50]
Olaparib DM8QB1D Major Decreased metabolism of Posaconazole caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [47]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Rucaparib. Ovarian cancer [2C73] [53]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Triclabendazole. Parasitic worm infestation [1F90] [53]
Istradefylline DM20VSK Major Decreased metabolism of Posaconazole caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [123]
Pimavanserin DMR7IVC Major Decreased metabolism of Posaconazole caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [124]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Posaconazole and Macimorelin. Pituitary gland disorder [5A60-5A61] [125]
Lefamulin DME6G97 Major Decreased metabolism of Posaconazole caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [126]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Posaconazole caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [127]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Degarelix. Prostate cancer [2C82] [50]
Enzalutamide DMGL19D Moderate Decreased metabolism of Posaconazole caused by Enzalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [128]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Relugolix. Prostate cancer [2C82] [50]
Darolutamide DMV7YFT Moderate Decreased clearance of Posaconazole due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [129]
Silodosin DMJSBT6 Major Decreased metabolism of Posaconazole caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [47]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Levomepromazine. Psychotic disorder [6A20-6A25] [53]
Ambrisentan DMD1QXW Minor Decreased metabolism of Posaconazole caused by Ambrisentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [130]
Riociguat DMXBLMP Moderate Decreased clearance of Posaconazole due to the transporter inhibition by Riociguat. Pulmonary hypertension [BB01] [47]
Everolimus DM8X2EH Major Decreased metabolism of Posaconazole caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [47]
Axitinib DMGVH6N Major Decreased metabolism of Posaconazole caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [47]
Temsirolimus DMS104F Major Increased metabolism of Posaconazole caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [47]
Ciclesonide DM2NA4K Moderate Decreased metabolism of Posaconazole caused by Ciclesonide mediated inhibition of CYP450 enzyme. Respiratory system disease [CB40-CB7Z] [131]
Upadacitinib DM32B5U Major Decreased metabolism of Posaconazole caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [132]
Tofacitinib DMBS370 Major Decreased metabolism of Posaconazole caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [47]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Posaconazole and Iloperidone. Schizophrenia [6A20] [53]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Paliperidone. Schizophrenia [6A20] [53]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Posaconazole and Amisulpride. Schizophrenia [6A20] [47]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Asenapine. Schizophrenia [6A20] [53]
Avanafil DM75CXN Major Decreased metabolism of Posaconazole caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [47]
Voxelotor DMCS6M5 Major Decreased metabolism of Posaconazole caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [133]
LDE225 DMM9F25 Major Decreased metabolism of Posaconazole caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [134]
Larotrectinib DM26CQR Major Decreased metabolism of Posaconazole caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [47]
Trabectedin DMG3Y89 Major Decreased metabolism of Posaconazole caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [47]
Armodafinil DMGB035 Minor Decreased metabolism of Posaconazole caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [47]
LEE011 DMMX75K Major Decreased metabolism of Posaconazole caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [135]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Posaconazole and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [53]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [50]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Pitolisant. Somnolence [MG42] [53]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [53]
Pomalidomide DMTGBAX Moderate Decreased metabolism of Posaconazole caused by Pomalidomide mediated inhibition of CYP450 enzyme. Systemic sclerosis [4A42] [47]
Fostamatinib DM6AUHV Major Decreased metabolism of Posaconazole caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [136]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Posaconazole due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [137]
As-1670542 DMV05SW Moderate Decreased metabolism of Posaconazole caused by As-1670542 mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [50]
Apixaban DM89JLN Major Decreased clearance of Posaconazole due to the transporter inhibition by Apixaban. Thrombosis [DB61-GB90] [47]
Brilinta DMBR01X Major Decreased metabolism of Posaconazole caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [47]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Posaconazole and Lenvatinib. Thyroid cancer [2D10] [53]
Cabozantinib DMIYDT4 Major Decreased metabolism of Posaconazole caused by Cabozantinib mediated inhibition of CYP450 enzyme. Thyroid cancer [2D10] [47]
Saxagliptin DMGXENV Moderate Decreased metabolism of Posaconazole caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [50]
Elagolix DMB2C0E Major Decreased metabolism of Posaconazole caused by Elagolix mediated inhibition of CYP450 enzyme. Uterine fibroid [2E86] [138]
Fluticasone DMGCSVF Major Decreased metabolism of Posaconazole caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [139]
Betrixaban DM2C4RF Moderate Decreased clearance of Posaconazole due to the transporter inhibition by Betrixaban. Venous thromboembolism [BD72] [140]
⏷ Show the Full List of 185 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Carmellose sodium E00625 Not Available Disintegrant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Posaconazole 100 mg tablet 100 mg Delayed Release Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022003.
2 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
3 Structural insights into inhibition of sterol 14alpha-demethylase in the human pathogen Trypanosoma cruzi. J Biol Chem. 2010 Aug 13;285(33):25582-90.
4 BDDCS applied to over 900 drugs
5 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
10 A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity. Mycoses. 2006;49 Suppl 1:2-6.
11 KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
12 Survey of computed tomography doses and establishment of national diagnostic reference levels in the Republic of Belarus. Radiat Prot Dosimetry. 2010 Apr-May;139(1-3):367-70.
13 Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos. 2004 Feb;32(2):267-71.
14 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
15 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
16 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
17 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
18 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
19 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
22 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
23 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
24 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
25 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
26 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
27 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
28 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
29 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
30 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
31 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
32 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
33 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
34 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
35 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
36 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
37 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
38 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
39 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
40 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
41 Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
42 Antifungal agents: mechanisms of action. Trends Microbiol. 2003 Jun;11(6):272-9.
43 Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9.
44 Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme. Arch Biochem Biophys. 2006 Nov 1;455(1):61-7.
45 Biological spectra analysis: Linking biological activity profiles to molecular structure. Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):261-6.
46 Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homolo... Antimicrob Agents Chemother. 2008 Oct;52(10):3597-603.
47 Cerner Multum, Inc. "Australian Product Information.".
48 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
49 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
50 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
51 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
52 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
53 Canadian Pharmacists Association.
54 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
55 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
56 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
57 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
58 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
59 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
60 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
61 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
62 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
63 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
64 Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9. [PMID: 2547410]
65 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
66 Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
67 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
68 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
69 Product Information. Breo Ellipta (fluticasone-vilanterol). GlaxoSmithKline, Research Triangle Park, NC.
70 Product Information. Fetzima (levomilnacipran). Forest Pharmaceuticals, St. Louis, MO.
71 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
72 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
73 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
74 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
75 Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33. [PMID: 2330488]
76 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
77 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
78 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
79 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
80 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
81 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
82 Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR "Omeprazole significantly reduces posaconazole serum trough level." Clin Infect Dis 48 (2009): 839. [PMID: 19220151]
83 Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
84 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
85 Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
86 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
87 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
88 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
89 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
90 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
91 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
92 Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
93 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
94 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
95 Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086]
96 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
97 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
98 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
99 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
100 Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
101 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
102 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
103 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
104 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
105 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
106 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
107 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
108 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
109 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
110 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
111 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
112 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
113 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
114 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
115 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
116 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
117 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
118 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
119 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
120 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
121 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
122 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
123 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
124 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
125 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
126 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
127 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
128 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
129 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
130 Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
131 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
132 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
133 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
134 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
135 Product Information. Kisqali (ribociclib). Novartis Pharmaceuticals, East Hanover, NJ.
136 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
137 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
138 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
139 Arrington-Sanders R, Hutton N, Siberry GK "Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents." Pediatr Infect Dis J 25 (2006): 1044-1048. [PMID: 17072128]
140 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.